[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06558201":3,"trial-entities:NCT06558201":161,"trial-summary:NCT06558201":166},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":33,"primary_purpose":34,"phases":35,"enrollment_info":37,"interventions":40,"primary_outcomes":46,"secondary_outcomes":69,"sex":133,"minimum_age":134,"maximum_age":135,"healthy_volunteers":15,"eligibility_criteria":136,"std_ages":142,"locations":144,"central_contacts":154,"overall_officials":155,"references":159,"see_also_links":160},"NCT06558201","2023P002849-2","Open Label Extension Study of NCT06221852","Open Label Extension Study of NCT06221852 of the Ketogenic Diet in Participants With First Episode Bipolar Disorder.","ENROLLING_BY_INVITATION","2027-12-30","2026-06","2026-06-25","2024-08-28","Mclean Hospital","OTHER",false,"This is a 12-week open-label extension study for participants completing study NCT06221852.","In this 12-week single arm open label extension study of NCT06221852, the investigators aim to assess the longer term efficacy, safety and tolerability of the ketogenic diet in participants completing the randomized study phase of NCT06221852. Investigators will assess longer term effects on energy metabolism, insulin resistance and psychiatric symptoms.",[19,20,21],"Bipolar I Disorder","Schizoaffective Disorder","Psychosis",[23,24,25,26,27,28,29,30,31,32],"First episode psychosis","Ketogenic diet","Keto","Brain energy metabolism","Insulin resistance","Schizoaffective disorder","Bipolar disorder","Magnetic resonance spectroscopy (MRS)","Redox","Creatine kinase","INTERVENTIONAL","TREATMENT",[36],"NA",{"count":38,"type":39},50,"ESTIMATED",[41],{"type":14,"name":24,"description":42,"armGroupLabels":43,"otherNames":44},"The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.",[24],[45],"Keto diet",[47,51,54,57,60,63,66],{"measure":48,"description":49,"timeFrame":50},"Change in brain redox nicotinamide adenine dinucleotide metabolites ratio (NAD+\u002FNADH)","Change from baseline to week 24 in NAD+\u002FNADH as measured by in vivo phosphorus magnetic resonance spectroscopy (31P-MRS).","24 weeks",{"measure":52,"description":53,"timeFrame":50},"Change in brain creatine kinase forward reaction rate (kf)","Change from baseline to week 24 in creatine kinase forward reaction rate (kf) as measured by 31P magnetization transfer (MT) MRS.",{"measure":55,"description":56,"timeFrame":50},"Change in insulin resistance","Change from baseline to week 24 of insulin resistance measured using the homeostatic model assessment of insulin resistance (HOMA-IR) using fasting blood glucose and insulin levels.",{"measure":58,"description":59,"timeFrame":50},"Change in psychotic symptoms","Change from baseline to week 24 in Positive and Negative Syndrome Scale (PANSS) total score. Scores range from 30-210; a higher score indicates a higher level of psychotic symptoms.",{"measure":61,"description":62,"timeFrame":50},"Change in depressive symptoms","Change from baseline to week 24 in Hamilton Rating Scale for Depression (HAM-D) total score. Scores range from 0-52; a higher score indicates a higher level of depression.",{"measure":64,"description":65,"timeFrame":50},"Change in mania symptoms","Change from baseline to week 24 in Young Mania Rating Scale (YMRS) total score. Scores range from 0-60. A higher score indicates a more severe illness.",{"measure":67,"description":68,"timeFrame":50},"Change in Clinical Global Impression (CGI) Scale","Change from baseline to week 24 in Clinical Global Impression (CGI) Scale. Scores range from 1-7; a higher score indicates higher severity of illness.",[70,73,76,79,82,85,88,91,94,97,100,103,106,109,112,115,118,121,124,127,130],{"measure":71,"description":72,"timeFrame":50},"Change in body weight","Change from baseline to week 24 in participant body weight in kilograms, as measured using a standing scale.",{"measure":74,"description":75,"timeFrame":50},"Change in glycated hemoglobin (Hemoglobin A1c) level","Change from baseline to week 24 in fasting Hemoglobin A1c level.",{"measure":77,"description":78,"timeFrame":50},"Change in triglyceride levels","Change from baseline to week 24 in fasting triglyceride levels.",{"measure":80,"description":81,"timeFrame":50},"Change in low-density lipoprotein (LDL) levels","Change from baseline to week 24 in fasting LDL levels",{"measure":83,"description":84,"timeFrame":50},"Change in high-density lipoprotein (HDL) levels","Change from baseline to week 24 in fasting HDL levels",{"measure":86,"description":87,"timeFrame":50},"Change in high-sensitivity C-reactive protein (hs-CRP) levels","Change from baseline to week 24 in fasting hs-CRP levels.",{"measure":89,"description":90,"timeFrame":50},"Change in brain gamma-aminobutyric acid (GABA) concentration","Change from baseline to week 24 in GABA concentration measured by proton magnetic resonance spectroscopy.",{"measure":92,"description":93,"timeFrame":50},"Change in brain glutamate metabolite concentration","Change from baseline to week 24 in glutamate metabolite concentration measured by proton magnetic resonance spectroscopy.",{"measure":95,"description":96,"timeFrame":50},"Change in brain glutathione (GSH)","Change from baseline to week 24 in brain GSH measured by proton magnetic resonance spectroscopy.",{"measure":98,"description":99,"timeFrame":50},"Change in brain Phosphocreatine (PCr)","Changes from baseline to week 24 in PCr concentration as measured by in vivo 31P-MRS.",{"measure":101,"description":102,"timeFrame":50},"Change in brain pH","Change from baseline to week 24 in pH as measured by in vivo 31P MRS",{"measure":104,"description":105,"timeFrame":50},"Change in brain inorganic phosphate concentration","Change from baseline to week 24 in inorganic phosphate (Pi) concentration as measured by in vivo 31P MRS.",{"measure":107,"description":108,"timeFrame":50},"Change in adverse events","Change from baseline to week 24 in adverse events.",{"measure":110,"description":111,"timeFrame":50},"Change in anxiety symptoms","Change from baseline to week 24 from baseline to week 12 in Hamilton Anxiety Rating Scale (HAM-A) total score. Scores range from 0 - 56; a higher score indicates a higher level of anxiety.",{"measure":113,"description":114,"timeFrame":50},"Change in stress symptoms","Change from baseline to week 24 in Depression Anxiety Stress Scales (DASS-42) Stress Subscale score. Scores range from 0-42; a higher score indicates a higher level of stress.",{"measure":116,"description":117,"timeFrame":50},"Change in cognitive performance","Change from baseline to week 24 in Matrics Consensus Cognitive Battery (MCCB) Total Score. Scores range from 0.00% - 100.00%; a higher score indicates higher cognition.",{"measure":119,"description":120,"timeFrame":50},"Change in Global Functioning Scale (GFS) - Social and Role total score","Change from baseline to week 24 in Global Functioning Scale (GFS) - Social and Role total score. Scores range from 6-60; a lower score indicates worse social and role functioning.",{"measure":122,"description":123,"timeFrame":50},"Change in blood NAD\u002FNADH+ ratio","Change from baseline to week 24 in blood NAD\u002FNADH+ ratio.",{"measure":125,"description":126,"timeFrame":50},"Change in blood GSH\u002FGSSH ratio","Change from baseline to week 24 in blood GSH\u002FGSSH ratio.",{"measure":128,"description":129,"timeFrame":50},"Change in growth differentiation factor 15 (GDF15)","Change from baseline to week 24 in blood and saliva GDF15 levels.",{"measure":131,"description":132,"timeFrame":50},"Change in cell-free mitochondrial DNA (cf-mtDNA)","Change from baseline to week 24 in blood and saliva cf-mtDNA levels.","ALL","18 Years","45 Years",{"inclusion":137,"exclusion":139,"raw_text":141},[138],"Participants who met original entry criteria in, and completed, the randomized 12-week study of NCT06221852.",[140],"No longer meeting original entry criteria from the randomized 12-week study of NCT06221852.","Inclusion Criteria:\n\n* Participants who met original entry criteria in, and completed, the randomized 12-week study of NCT06221852.\n\nExclusion Criteria:\n\n-No longer meeting original entry criteria from the randomized 12-week study of NCT06221852.",[143],"ADULT",[145],{"facility":146,"city":147,"state":148,"zip":149,"country":150,"geoPoint":151},"McLean Hospital","Belmont","Massachusetts","02487","United States",{"lat":152,"lon":153},42.39593,-71.17867,[],[156],{"name":157,"affiliation":13,"role":158},"Virginie-Anne Chouinard, MD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":162,"biomarkers":165},[163,164,20],"Bipolar I disorder","First Episode Psychosis",[],{"nct_id":4,"found":15,"summary":167,"prompt_version":167},null]